HLB Therapeutics Co.,Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 0.0009 million compared to KRW 23.11 million a year ago. Net loss was KRW 1,216.69 million compared to KRW 1,965.07 million a year ago.

Basic loss per share from continuing operations was KRW 17.3913 compared to KRW 29.4056 a year ago. Diluted loss per share from continuing operations was KRW 17.3913 compared to KRW 29.4056 a year ago. Basic loss per share was KRW 17.3913 compared to KRW 60.8696 a year ago.